Local & Trade News | Aug 04, 2017

Astellas appoints DKSH to market and sell Prograf and Berasil in Korea

DKSH, the leading Market Expansion Services Provider with a focus on Asia, has been appointed by Astellas, a leading Japanese pharmaceutical company specialized in urology products, to drive sales of its Prograf (AI) Cap and Berasil Tab products in Korea.



Media release

Seoul, Korea, August 04, 2017 – DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will provide marketing and sales services for Prograf (AI) Cap and Berasil Tab products from Astellas. Prograf and Berasil are highly known products for rheumatoid arthritis and antiplatelet agents respectively. DKSH will ensure access to clinics and semi-hospitals, while Astellas Korea will focus on general hospitals in Korea.

 

Astellas, headquartered in Tokyo, Japan, is a leading pharmaceutical company, focusing on urology and transplantation. It is the No.1 Japanese pharmaceutical company in terms of sales volume in Korea.

 

“We are excited that Astellas Korea has selected DKSH as its strategic partner. DKSH's proven competitive capabilities in clinic networking and its strict sales compliance standards will help Astellas to drive sales excellence in the Korean market. Partnering with Astellas underlines DKSH's strong position as the leading growth partner for healthcare companies in Korea,” said Danny Lee, Business Unit Manager, Business Unit Healthcare, DKSH Korea.

 

The agreement is an extension of a collaboration between both companies that also spans Hong Kong, Malaysia, Taiwan, Singapore and Vietnam.

For further information please contact:

 

DKSH Korea Ltd.

Nicole Noh

Brand Champion

Phone +82 2 2192 9500

nicole.noh@dksh.com


Contact Us

Looking for a trusted partner?

Contact us to explore how DKSH can help you achieve your goals.